The phase III COMMIT trial demonstrates that intensifying first-line immunotherapy with chemotherapy and antiangiogenic therapy can substantially improve outcomes for patients with deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC). In this randomized study, the addition of fluorouracil, oxaliplatin, and leucovorin calcium (modified (m)FOLFOX6) chemotherapy and bevacizumab to the PD-L1 inhibitor […]

Patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) represent a biologically distinct subgroup with historically poor outcomes and limited first-line, biomarker-driven treatment options. Within this context, the Phase III BREAKWATER trial is evaluating early integration of targeted BRAF inhibition (encorafenib) plus EGFR blockade (cetuximab) alongside standard chemotherapy backbones in this high-risk population. Cohort 3 evaluated […]

Patients with refractory metastatic colorectal cancer (mCRC) and microsatellite-stable (MSS) disease have limited treatment options and historically derive minimal benefit from immunotherapy. In the phase III STELLAR-303 trial, zanzalintinib plus atezolizumab significantly improved overall survival (OS) and progression-free survival (PFS) compared with regorafenib in previously treated MSS mCRC, including patients with and without liver metastases. […]

First randomized trial shows aspirin 100mg daily improves disease-free survival in PIK3CA-mutant colon cancer patients.

EOCRC exhibited significantly higher TMB compared with LOCRC in hypermutated tumors, with distinct gene mutation patterns including elevated APC and KRAS.

CRC screening in ages 45-49 jumped from 20.8% to 33.7% post-USPSTF guidelines, but gains limited to educated, insured populations.

MT-sDNA screening showed 0.2% CRC detection rate and 73% false-positive rate, raising questions about effectiveness in average-risk patients.